FDA review extension puts spotlight on Travere Therapeutics

The latest move in Travere Therapeutics (TVTX) comes after the FDA extended its review of the supplemental New Drug Application for Filspari. The agency set a new April 2026 action date that reshapes the timeline investors are watching.

Travere’s share price has reacted quickly to the FDA update, with a recent 9.5% jump and a 10.65% 1 month share price return. However, the year to date share price return of a 19.84% decline contrasts with a very large 134.84% 1 year total shareholder return, suggesting that momentum has cooled after a strong run.

If this regulatory update has you reviewing your healthcare exposure, it could be a good time to look at other potential rare disease and biotech ideas through 34 healthcare AI stocks

With shares up sharply over 1 year and trading about 34% below the average analyst price target, plus a very large 67% intrinsic discount, should you see TVTX as mispriced value, or has the market already baked in future growth?

Most Popular Narrative: 25.2% Undervalued

Travere’s fair value from the most followed narrative sits at $42.36 against a last close of $31.68, putting the FDA extension in a broader valuation context.

Strong financial discipline, increasing recurring revenue, and efficient regulatory progress provide resources for pipeline advancement and future commercial launches.

Travere's strengthening financial position driven by rapid product sales growth, increased international out licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management sets a foundation for positive net earnings, while securing resources for continued pipeline development and future commercial launches.

Curious what kind of revenue ramps, margin shifts, and future earnings multiple are baked into that price tag? The narrative leans on bold growth and profitability assumptions that do a lot of heavy lifting for that $42.36 fair value.

Result: Fair Value of $42.36 (UNDERVALUED)

However, the story can change quickly if FILSPARI faces tougher competition or regulatory delays, especially because Travere relies heavily on a single primary revenue driver.

Next Steps

With mixed signals across valuation, momentum, and the regulatory timeline, it helps to see the full picture for yourself rather than rely on one narrative. To weigh the upside against the concerns in a balanced way, review the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with a single stock, you risk missing out on other opportunities the screener is already surfacing across different styles and risk profiles.

• Target potential mispricings by scanning the market for companies flagged as 64 high quality undervalued stocks.
• Strengthen portfolio resilience by focusing on businesses highlighted in the 72 resilient stocks with low risk scores.
• Get ahead of the crowd by researching smaller names surfaced by the screener containing 24 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.